Dry Eye Disease Market expected to rise | Companies – TearSolutions, HanAll Biopharma, Aldeyra Therapeutics, RegeneRx Biopharmaceuticals, Mitotech, Novaliq, Oyster Point Pharma, Aerie Pharmaceuticals

Dry Eye Disease Market expected to rise | Companies - TearSolutions, HanAll Biopharma, Aldeyra Therapeutics, RegeneRx Biopharmaceuticals, Mitotech, Novaliq, Oyster Point Pharma, Aerie Pharmaceuticals
Dry Eye Disease Market
DelveInsight’s “Dry Eye Disease Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Dry Eye Disease, historical and forecasted epidemiology as well as the Dry Eye Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Dry Eye Disease market growth is driven by factors like increase in the prevalence of Dry Eye Disease, investments in research and development, entry of emerging therapies during the study period 2019-2032.

The Dry Eye Disease market report also offers comprehensive insights into the Dry Eye Disease market size, share, Dry Eye Disease epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Dry Eye Disease market size growth forward. 

Some of the key highlights from the Dry Eye Disease Market Insights Report:

  • Several key pharmaceutical companies, including TearSolutions, HanAll Biopharma, Aldeyra Therapeutics, RegeneRx Biopharmaceuticals, Mitotech, Novaliq, Oyster Point Pharma, Aerie Pharmaceuticals, Azura Ophthalmics, Stuart Therapeutics, Surface Ophthalmics, Glaukos Corporation, and others, are developing novel products to improve the Dry Eye Disease treatment outlook. 
  • The total Dry Eye Disease market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
  • As per DelveInsight analysis, the Dry Eye Disease market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Dry Eye Disease Market Landscape

Dry Eye Disease Overview 

Dry eye disease is defined as a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and subacute inflammation of the ocular surface. Dry eyes can occur when tear production and drainage are not in balance. People with dry eyes either do not produce enough tears or their tears are of a poor quality. Dry eyes can develop for many reasons, including: Age, gender, medications, medical conditions (people with rheumatoid arthritis, diabetes, and thyroid problems are more likely to have symptoms of dry eyes.

Also, problems with inflammation of the eyelids (blepharitis), inflammation of the surfaces of the eye, or the inward or outward turning of eyelids can cause dry eyes to develop) and other factors such as long-term use of contact lenses can be a factor in the development of dry eyes. Refractive eye surgeries, such as LASIK, can decrease tear production and contribute to dry eyes. People with dry eyes may experience irritated, gritty, scratchy or burning eyes; a feeling of something in their eyes; excess watering; and blurred vision. Symptoms include: Redness, stinging, scratching, or burning sensations, light sensitivity, watery eyes, stringy mucus near the eye and a blurry Vision.

Dry eyes can be diagnosed through a comprehensive eye examination. Treatments for dry eyes aim to restore or maintain the normal amount of tears in the eye to minimize dryness and related discomfort and to maintain eye health. The primary approaches used to manage and treat dry eyes include adding tears using over-the-counter artificial tear solutions, conserving tears, increasing tear production, and treating the inflammation of the eyelids or eye surface that contributes to the dry eyes.

Do you know the treatment paradigms for different countries? Download our Dry Eye Disease Market Sample Report

Dry Eye Disease Epidemiology Segmentation 

DelveInsight’s Dry Eye Disease market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Dry Eye Disease historical patient pools and forecasted Dry Eye Disease patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Dry Eye Disease Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

  • Dry Eye Disease Prevalence 
  • Age-Specific Dry Eye Disease Prevalence 
  • Gender-Specific Dry Eye Disease Prevalence 
  • Diagnosed and Treatable Cases of Dry Eye Disease

Visit for more @ Dry Eye Disease Epidemiological Insights

Dry Eye Disease Treatment Market 

The Dry Eye Disease market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Dry Eye Disease market trends by analyzing the impact of current Dry Eye Disease therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Dry Eye Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Dry Eye Disease market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Dry Eye Disease market in 7MM is expected to witness a major change in the study period 2019-2032.

Dry Eye Disease Emerging Therapy Assessment

Reproxalap: Aldeyra Therapeutics

Reproxalap, is a novel small molecule drug candidate for Dry Eye. By inhibiting RASP, which are elevated in a variety of inflammatory diseases, reproxalap represents a novel mechanism for diminishing ocular inflammation in dry eye disease. In a number of clinical trials, reproxalap demonstrated consistent statistically significant and clinically relevant activity. In a Phase II b clinical trial, Aldeyra’s lead RASP inhibitor, reproxalap, demonstrated broad activity across a variety of symptoms and signs in patients with dry eye disease.

Timbetasin: RegeneRx Biopharmaceuticals

RGN-259, a Tβ4-based sterile and preservative-free eye drop, as a novel treatment for dry eye and neurotrophic keratitis (NK). RGN-259 represents a new approach to corneal healing, as there is currently no pharmaceutical agent that has shown corneal repair and anti-inflammatory properties. Preclinical studies have shown that Tβ4 promotes cell migration, increases cell-cell and cell-matrix contacts through increase laminin-5 production, and reduces both apoptosis and inflammation in the cornea.

Visomitin: Mitotech

Visomitin, contains a novel small molecule cardiolipin peroxidation inhibitor, specifically developed to target ophthalmic disorders such as dry eye syndrome, uveitis and age-related macular degeneration, in an eye drop formulation for ease of administration. Visomitin has been developed to deliver a highly active antioxidant, plastoquinone, directly into mitochondria. Visomitin has been shown to accumulate in mitochondria in an extremely targeted and efficient manner. The biochemical characteristics of the mitochondrial membrane and the unique properties of Visomitin direct it into the inner leaflet of the inner mitochondrial membrane with high precision. Once positioned in mitochondria, the molecule acts as a targeted scavenger of reactive oxygen species (ROS) and as a very efficient cardiolipin protector.

Dry Eye Disease Key Companies

  • TearSolutions
  • HanAll Biopharma
  • Aldeyra Therapeutics
  • RegeneRx Biopharmaceuticals
  • Mitotech
  • Novaliq
  • Oyster Point Pharma
  • Aerie Pharmaceuticals
  • Azura Ophthalmics
  • Stuart Therapeutics
  • Surface Ophthalmics
  • Glaukos Corporation

For more information, visit Dry Eye Disease Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Dry Eye Disease Market Report:

  • 10 Years Forecast
  • 7MM Coverage 
  • Descriptive overview of Dry Eye Disease, causes, signs and symptoms, diagnosis, treatment
  • Comprehensive insight into Dry Eye Disease epidemiology in the 7MM
  • Dry Eye Disease marketed and emerging therapies 
  • Dry Eye Disease companies
  • Dry Eye Disease market drivers and barriers 

Key Questions Answered in the Dry Eye Disease Market Report 2032:

  • What was the Dry Eye Disease market share distribution in 2019, and how would it appear in 2032?
  • What is the total Dry Eye Disease market size and the market size by therapy across the 7MM for the study period (2019-32)?
  • What are the important findings from 7MM, and which country will have the greatest Dry Eye Disease market size from 2019-32?
  • During the study period (2019-2032), at what CAGR is the Dry Eye Disease market projected to expand at 7MM?

Table of Contents:

1 Dry Eye Disease Market Key Comprehensive Insights 

2 Dry Eye Disease Market Report Introduction

3 Competitive Intelligence Analysis for Dry Eye Disease

4 Dry Eye Disease Market Analysis Overview at a Glance

5 Executive Summary of Dry Eye Disease

6 Dry Eye Disease Epidemiology and Market Methodology

7 Dry Eye Disease Epidemiology and Patient Population

8 Dry Eye Disease Patient Journey

9 Dry Eye Disease Treatment Algorithm, Dry Eye Disease Current Treatment, and Medical Practices

10 Key Endpoints in Dry Eye Disease Clinical Trials

11 Dry Eye Disease Marketed Therapies 

12 Dry Eye Disease Emerging Therapies

13 Dry Eye Disease: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Dry Eye Disease

16 Dry Eye Disease Market Key Opinion Leaders Reviews

18 Dry Eye Disease Market Drivers

19 Dry Eye Disease Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Dry Eye Disease Epidemiology 2032

DelveInsight’s “Dry Eye Disease – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Dry Eye Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Dry Eye Disease Pipeline 2023

“Dry Eye Disease Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Dry Eye Disease market. A detailed picture of the Dry Eye Disease pipeline landscape is provided, which includes the disease overview and Dry Eye Disease treatment guidelines. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/